Abattis Partners with Vancouver-Based Craft Brewer to Develop Hemp-Infused, Cannabinoid-Rich, THC-Free Craft Beer
January 22 2018 - 9:02AM
Abattis Bioceuticals Corp. (the
"
Company" or "
Abattis") (CSE:ATT)
(OTC:ATTBF) is pleased to announce the formation of a new
partnership (the “
Partnership”) with Faculty
Brewing Co. (“
Faculty Brewing”), a Vancouver-based
craft brewery, to develop a hemp-infused, cannabinoid-rich,
THC-free craft beer. Pursuant to a research services agreement
between Abattis and Faculty Brewing, Abattis will conduct research
and development activities related to the development of a
hemp-infused, cannabinoid-rich, THC-free craft beer, or a line of
such beers, for Faculty Brewing.
“Our exciting partnership with Faculty Brewing
positions us as one of the first Canadian companies to secure an
agreement for research and development, analytical and regulatory
services relating to a hemp- and cannabis-infused beverage,” said
Rob Abenante, President and CEO of Abattis. “By aiming to develop a
line of functional beers, each based on a different type of hemp
extract, we hope to have a product that is compliant and
market-ready as soon as Health Canada releases its new regulatory
framework for hemp and cannabis-infused beverages,” added Mr.
Abenante.
Northern Vine Laboratories
(“Northern Vine”) has been contracted by Abattis
to provide cannabinoid-rich, THC-free, hemp extract and to carry
out research, development and analytical testing related to the
formulation of a unique hemp- and cannabis-infused beer. Northern
Vine is a Licensed Dealer under the provisions of the Canadian
Controlled Drugs and Substances Act. As a Licensed Dealer, Northern
Vine has the ability to import/export cannabis and cannabis oils,
as well as the right to conduct certain activities related to the
manipulation, formulation, dosage form, and strength or package
size of cannabis, including mixtures with other additives,
controlled substances, and non-controlled substances. Northern Vine
is co-owned by Abattis and Emerald Health Therapeutics
(“Emerald”) (TSX-V:EMH) (OTCQX:EMHTF), which is a
controlling shareholder.
“Having the Northern Vine team on board ensures
the final product will deliver a precise and consistent amount of
pesticide-free cannabinoids in every single bottle,” said Dr. David
Galvez, Senior Science Advisor for Northern Vine and Abattis.
The Partnership follows Abattis’s January 9,
2018 announcement respecting its proposed exclusive agreement to
offer technical advice regarding the commercialization of cannabis
products sold in British Columbia’s Alliance of Beverage Licensees
(ABLE BC) member stores.
About Northern Vine
Northern Vine Labs™ is licensed by Health Canada
(Licensed Dealer) for the possession of cannabis and related active
ingredients, as well as the production of extracts for the purpose
of analysis. Northern Vine Labs™ product certification and quality
assurances programs incorporate global best practices and
procedures for application in the legal Canadian cannabis market.
Northern Vine is a subsidiary of Emerald Health Therapeutics, which
Abattis retains a 47% equity interest.
About Abattis Bioceuticals
Corp.
Abattis is a life sciences and biotechnology
company which aggregates, integrates, and invests in cannabis
technologies and biotechnology services for the legal cannabis
industry developing in Canada. The Company has successfully
developed and licensed natural health products, medicines,
extractions, and ingredients for the biologics, nutraceutical,
bioceutical, and cosmetic markets. The Company is also seeking to
acquire exclusive intellectual property rights to agricultural
technologies to be employed in extraction and processing of
botanical ingredients and compounds. The Company follows strict
standard operating protocols, and adheres to the applicable laws of
Canada and foreign jurisdictions.
ON BEHALF OF THE BOARD,ABATTIS BIOCEUTICALS
CORP.
“Rob Abenante"Robert Abenante, President & CEO
For more information, please visit the Company's
website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at
(604) 336-0881 or at news@abattis.com.
FORWARD LOOKING
INFORMATION This press release contains
forward-looking statements. The use of any of the words
"anticipate", "continue", "estimate", "expect", "may", "will",
"project", “intends”, "should", "believe" and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements in this press release include statements
regarding: Abattis’s activities pursuant to its research services
agreement with Faculty Brewing; and Abattis’s hope to have a
compliant and market-ready product ready when Health Canada
releases its new regulatory framework for hemp- and
cannabis-infused beverages. Although the Company believes that the
expectations and assumptions on which the forward-looking
statements are based are reasonable, undue reliance should not be
placed on the forward-looking statements because the Company can
give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by
their very nature they involve inherent risks and uncertainties,
including: that Abattis’s will carry out its responsibilities
pursuant to its research services agreement with Faculty Brewing;
that Abattis will have a compliant and market-ready product ready
when Health Canada releases its new regulatory framework for hemp-
and cannabis-infused beverages; that the Company will not be able
to execute its proposed business plan in the time required or at
all due to regulatory, financial or other issues; that the
Company’s competitors may develop competing technologies; changes
in regulatory requirements; and other factors beyond the Company’s
control. Additional risk factors are included in the Company's
Management's Discussion and Analysis, available under the Company's
profile on www.sedar.com. The forward-looking statements are made
as at the date hereof and the Company disclaims any intent or
obligation to publicly update any forward-looking statements, where
because of new information, future events or results, or otherwise,
except as required by applicable securities laws.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024